US
CA
NZ
UK
AU
IND
Last update at 2025-07-08T15:14:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
| Income before tax | -7.68732M | -11.72744M | -6.45794M | -1.10262M | -0.23012M |
| Minority interest | - | - | - | - | - |
| Net income | -7.68732M | -11.72744M | -6.45794M | -1.17431M | -0.23012M |
| Selling general administrative | 2.26M | 3.12M | 5.72M | 0.86M | 0.23M |
| Selling and marketing expenses | - | 0.17M | 1.72M | 0.08M | - |
| Gross profit | - | - | - | - | - |
| Reconciled depreciation | - | - | - | - | - |
| Ebit | - | -4.08179M | -6.44203M | -1.09838M | -0.22991M |
| Ebitda | - | 3.58M | -6.41847M | -1.09401M | -0.22970M |
| Depreciation and amortization | - | 0.00380M | 0.00598M | 0.00101M | 0.00018M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -6.45319M | -4.08179M | -6.44203M | -1.09838M | -0.22991M |
| Other operating expenses | - | 4.08M | 6.44M | 1.10M | 0.23M |
| Interest expense | - | - | 0.00000M | 0.00000M | 0.00000M |
| Tax provision | - | - | - | - | - |
| Interest income | 0.02M | 0.02M | 0.00766M | 0.00014M | 0.00000M |
| Net interest income | 0.02M | 0.02M | 0.00766M | 0.00014M | 0.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | 7.64M | 0.00993M | 0.07M | 0.00003M |
| Total revenue | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 6.45M | 4.08M | 6.44M | 1.10M | 0.23M |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | -1.25898M | -7.66142M | -0.02356M | -0.00438M | -0.00021M |
| Discontinued operations | - | - | - | -0.07169M | -0.01324M |
| Net income from continuing ops | -7.68732M | -11.72744M | -6.45794M | -1.10262M | -0.23012M |
| Net income applicable to common shares | - | -11.72744M | -6.45794M | -1.17431M | -0.23012M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
| Total assets | 0.11M | 0.87M | 8.50M | 10.46M | 0.31M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | - | - | - | - | 0.07M |
| Total liab | 3.49M | 1.64M | 0.33M | 0.90M | 0.12M |
| Total stockholder equity | -3.37206M | -0.77353M | 8.18M | 9.56M | 0.19M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | - | - | 0.07M | - | - |
| Common stock | - | 17.05M | 14.76M | 10.75M | 0.57M |
| Capital stock | 21.99M | 17.05M | 14.76M | 10.75M | 0.57M |
| Retained earnings | -27.29560M | -19.60829M | -8.02245M | -1.56451M | -0.39135M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | - | 0.15M | 0.23M | - | - |
| Cash | 0.00098M | 0.14M | 0.59M | 2.42M | 0.23M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 3.49M | 1.64M | 0.33M | 0.90M | 0.12M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | - | - | - | - | - |
| Short term debt | - | - | - | - | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | - | - | - | - | - |
| Other stockholder equity | - | 1.78M | 1.44M | 0.37M | 0.01M |
| Property plant equipment | - | - | - | - | - |
| Total current assets | 0.11M | 0.71M | 0.87M | 3.06M | 0.31M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -0.77353M | 0.78M | 2.16M | 0.19M |
| Short term investments | - | - | - | - | - |
| Net receivables | - | 0.21M | 0.13M | 0.05M | 0.00228M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 2.66M | 1.31M | 0.22M | 0.75M | 0.04M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.00000M | 0.15M | 7.63M | 7.40M | 0.07M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
| Investments | - | - | - | 0.06M | 0.00000M |
| Change to liabilities | - | 2.00M | -0.50145M | 0.18M | -0.01345M |
| Total cashflows from investing activities | - | - | - | 0.06M | 0.06M |
| Net borrowings | - | - | - | - | -0.05206M |
| Total cash from financing activities | 0.92M | 1.11M | 3.44M | 3.35M | 0.44M |
| Change to operating activities | - | -0.07452M | 0.42M | -0.63245M | 0.01M |
| Net income | -7.68732M | -11.72744M | -6.45794M | -1.10262M | -0.23012M |
| Change in cash | -0.14092M | -0.45122M | -1.82998M | 2.19M | 0.21M |
| Begin period cash flow | 0.14M | 0.59M | 2.42M | 0.23M | 0.02M |
| End period cash flow | 0.00098M | 0.14M | 0.59M | 2.42M | 0.23M |
| Total cash from operating activities | -1.05485M | -1.57461M | -5.29443M | -1.22689M | -0.23076M |
| Issuance of capital stock | 0.92M | 1.11M | 3.06M | 2.97M | 0.50M |
| Depreciation | - | - | - | - | - |
| Other cashflows from investing activities | - | - | - | 0.02M | 0.02M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | -0.00367M | 0.00064M | 0.05M | -0.00094M |
| Change to account receivables | - | 0.00367M | -0.00064M | -0.04603M | 0.00094M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | - | 0.00111M | 0.75M | 0.38M | -0.05206M |
| Change to netincome | - | 8.23M | 1.25M | 0.40M | 0.00000M |
| Capital expenditures | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 2.19M | 1.93M | -0.08335M | -0.44899M | -0.00064M |
| Stock based compensation | 0.15M | 0.50M | 1.14M | 0.35M | 0.00000M |
| Other non cash items | 3.08M | 7.73M | 0.11M | -0.02299M | 0.00000M |
| Free cash flow | -1.05485M | -1.57461M | -5.29443M | -1.22689M | -0.23076M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| BVAXF Biovaxys Technology Corp |
0.0001 0.35% | 0.03 | - | - | - | 8.86 | -2.8731 | |
| NVO Novo Nordisk A/S |
-0.5201 0.75% | 68.80 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
- -% | 70.12 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
10.38 2.26% | 469.79 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
18.29 3.40% | 556.40 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune-educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. Its product pipeline includes Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, which is in phase I clinical stage to treat the MAGE protein family member A9 in human cancers. It also develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health's proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine. In addition, the company operates T-Cell Antigen Discovery Program. It has agreement with AP Visionaries, Inc. to develop a proprietary DPX" formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies, namely those triggered by exposure to peanut/tree nuts or eggs. BioVaxys Technology Corp. is headquartered in Etobicoke, Canada.
146 Thirtieth Street, Etobicoke, ON, Canada, M8W 3D4
| Name | Title | Year Born |
|---|---|---|
| Mr. James Christopher Passin | Co-Founder, CEO & Director | 1972 |
| Mr. Kenneth E. Kovan | Co-Founder, Pres & COO | 1963 |
| Dr. David Berd | Co-Founder & Chief Medical Officer | 1943 |
| Mr. Craig William Loverock CA, CPA | Chief Financial Officer | 1971 |
| Mr. James Christopher Passin | Co-Founder, CEO, & Director | 1972 |
| Mr. Kenneth E. Kovan | Co-Founder, President & COO | 1963 |
| Dr. David Berd M.D. | Co-Founder & Chief Medical Officer | 1943 |
| Mr. Christopher P. Cherry | Chief Financial Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...